Celcuity is a Minneapolis biotechnology company developing gedatolisib, a cancer drug candidate for breast and prostate cancer patients. It last closed at $53.35 on Nov 20, down 5.26% on the day. The next earnings report for CELC is expected around Wed, Mar 24, 2027, after the close. For the quarter ended Sep 2026, CELC reported EPS of -$1.33. Over its last 8 reports the stock moved an average of 3.7% the session after earnings. Over the last 12 months CELC insiders bought $0 of stock on the open market and sold $327.6M, according to SEC Form 4 filings.
AI Auto Pilots
Is CELC in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CELC.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on CELCStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
CELC · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 21% below its 20 day and 30% below its 50 day average. It is 82% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), near oversold. The nearest support is the 52 week low at $53.20, and the nearest resistance the Pivot at $54.52.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 7.7%/day
Key levels
$151.0252 week high+183.1%
$97.15200 day average+82.1%
$81.21100 day average+52.2%
$72.24Swing high (Nov 9)+35.4%
$69.1950 day average+29.7%
$64.6420 day average+21.2%
$55.83Pivot R1+4.6%
$54.52Pivot+2.2%
$53.35Last close
$53.2052 week low−0.3%
$52.03Pivot S1−2.5%
Indicators
RSI (14)
30.08
Weak, oversold below 30
Neutral
MACD
-3.58
Below its signal line
Bearish
Stochastic
3.6
Near the bottom of its range
Oversold
ADX (14)
21.9
Weak trend
Williams %R
-99.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-176.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−20.1%
Change over 10 sessions
Bearish
ATR (14)
$4.09
Typical daily range, 7.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend, nearing oversold
Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 22.9%/day
Key levels
$151.0252 week high+183.1%
$97.15200 day average+82.1%
$81.21100 day average+52.2%
$72.24Swing high (Nov 9)+35.4%
$69.1950 day average+29.7%
$64.6420 day average+21.2%
$55.83Pivot R1+4.6%
$54.52Pivot+2.2%
$53.35Last close
$53.2052 week low−0.3%
$52.03Pivot S1−2.5%
Indicators
RSI (14)
32.27
Weak, oversold below 30
Neutral
MACD
-10.58
Below its signal line
Bearish
Stochastic
18.2
Near the bottom of its range
Oversold
ADX (14)
28.5
Trending down
Williams %R
-99.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-133.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−36.1%
Change over 10 sessions
Bearish
ATR (14)
$12.22
Typical daily range, 22.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for CELC
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CELC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow CELC usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for CELCHow many large options trades hit CELC, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in CELC in the last 90 days.
From SEC Form 4 filings by CELC's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CELC is in one of them and how their past CELC trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About Celcuity
Celcuity is a biotechnology company based in Minneapolis, Minnesota, that is developing gedatolisib, an investigational cancer treatment for solid tumors. The drug is given intravenously and works by blocking several parts of the PI3K, AKT and mTOR signaling pathway that tumors use to grow and survive. The company's main studies focus on advanced breast cancer and metastatic prostate cancer, and its drug is still in clinical trials and under regulatory review.